PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20813479-0	2011	NMR spectroscopy and surface tension measurements applied to the study of self-association of casopitant mesylate, a novel NK1 antagonist.	casopitant	94-104	tachykinin receptor 1	Homo sapiens	123-126
22020354-2	2011	Casopitant, a selective NK1 antagonist that achieves nearly complete receptor occupancy was studied in 2 randomized, placebo-controlled, double-blind, Phase II trials in depressed outpatients to test the hypothesis that nearly complete NK1 receptor occupancy is required to achieve antidepressant efficacy.	casopitant	0-10	tachykinin receptor 1	Homo sapiens	24-27
22020354-2	2011	Casopitant, a selective NK1 antagonist that achieves nearly complete receptor occupancy was studied in 2 randomized, placebo-controlled, double-blind, Phase II trials in depressed outpatients to test the hypothesis that nearly complete NK1 receptor occupancy is required to achieve antidepressant efficacy.	casopitant	0-10	tachykinin receptor 1	Homo sapiens	236-248
21993526-11	2012	CONCLUSION: These results indicate that after chronic dosing, casopitant can achieve a degree of NK(1) receptor occupancy higher than those that have previously been tested in studies of clinical depression.	casopitant	62-72	tachykinin receptor 1	Homo sapiens	97-111
21149541-3	2011	Casopitant is shown to be a substrate, an inhibitor, and an inducer of CYP3A4, and, because of this complex behavior, it was difficult to identify the primary mechanism by which it may give rise to drug-drug interactions (DDIs) of clinical relevance.	casopitant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
20813479-1	2011	The aggregation behaviour of casopitant mesylate, a new NK1 antagonist drug, was investigated by means of NMR spectroscopy and surface tension measurements.	casopitant	29-48	tachykinin receptor 1	Homo sapiens	56-59
20124517-1	2010	Casopitant, an antiemetic, is a neurokinin-1 receptor antagonist metabolized primarily by cytochrome P450 3A4 (CYP3A4).	casopitant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-109
20124517-1	2010	Casopitant, an antiemetic, is a neurokinin-1 receptor antagonist metabolized primarily by cytochrome P450 3A4 (CYP3A4).	casopitant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
20124517-8	2010	Coadministration of casopitant with strong inhibitors of CYP3A is likely to increase plasma exposure of casopitant, whereas coadministration with strong inducers of CYP3A is likely to decrease casopitant exposure and compromise efficacy.	casopitant	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-62
19428297-0	2009	Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.	casopitant	23-42	tachykinin receptor 1	Homo sapiens	46-73
18600583-1	2008	Casopitant, an inhibitor of the neurokinin-1 receptor, and its mesylate salt, are being developed by GlaxoSmithKline plc for the potential treatment of chemotherapy-induced nausea and vomiting (CINV), post-operative nausea and vomiting (PONV), as well as for anxiety, depression and insomnia.	casopitant	0-10	heparan sulfate proteoglycan 2	Homo sapiens	117-120